Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Cellectar Biosciences ( (CLRB) ).
On May 17, 2026, Cellectar Biosciences director Stefan D. Loren notified the board that he would not stand for reelection as a Class III director at the 2026 annual meeting, with his term to expire at that time, and the company emphasized that his decision did not stem from any disagreement over operations, policies, or practices. Effective July 8, 2026, Cellectar entered into a one-year consulting agreement with Loren, under which he will receive quarterly cash compensation and a stock option grant, with his existing and new options remaining exercisable for 10 years from their respective grant dates.
As part of a previously announced securities purchase agreement with institutional investors, Cellectar agreed to add a board representative selected by Nantahala Capital Management, leading to the appointment of Nantahala analyst Andrew Gu as a Class III director on May 18, 2026. Gu, who also joined the Audit Committee, brings biotechnology-focused investment experience and was appointed under terms that underscore Cellectar’s ongoing alignment with key institutional stakeholders and its evolving board composition following Loren’s transition to an advisory role.
The most recent analyst rating on (CLRB) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cellectar Biosciences stock, see the CLRB Stock Forecast page.
Spark’s Take on CLRB Stock
According to Spark, TipRanks’ AI Analyst, CLRB is a Neutral.
The score is held back primarily by weak financial performance (no revenue, ongoing losses and cash burn, and a thinner equity cushion), partly offset by a constructive earnings-call backdrop (strong clinical data and improved funding outlook) and moderately positive technical momentum. Valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on CLRB stock, click here.
More about Cellectar Biosciences
Cellectar Biosciences, Inc. operates in the biotechnology sector, focusing on developing and commercializing innovative therapies for patients, with a particular emphasis on the biotech investment and research ecosystem. The company engages with institutional investors and industry specialists to support its strategic initiatives and strengthen its governance and financial position.
Average Trading Volume: 1,002,819
Technical Sentiment Signal: Sell
Current Market Cap: $24.69M
For a thorough assessment of CLRB stock, go to TipRanks’ Stock Analysis page.